NYSE Listed Company Manual

NYSE to Commence Delisting Proceedings with Respect to the Warrants of InFinT Acquisition Corporation (IFIN.WS)

Retrieved on:

Tuesday, November 28, 2023

Professional Services, Finance, NYSE Listed Company Manual, New York Stock Exchange, NYSE, Security (finance), Warrant, Exchange, Committee

The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the redeemable warrants of InFinT Acquisition Corporation (the “Company”), exercisable for Class A ordinary shares at an exercise price of $11.50 per share (the “Warrants”) — ticker symbol IFIN.WS — from the NYSE.

Key Points:

The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the redeemable warrants of InFinT Acquisition Corporation (the “Company”), exercisable for Class A ordinary shares at an exercise price of $11.50 per share (the “Warrants”) — ticker symbol IFIN.WS — from the NYSE.
Trading in the Company’s Warrants will be suspended immediately.
Trading in the Company’s Class A ordinary shares — ticker symbol IFIN — and Units — ticker symbol IFIN.U — will continue on the NYSE.
NYSE Regulation has determined that the Company’s Warrants are no longer suitable for listing based on “abnormally low” price levels, pursuant to Section 802.01D of the Listed Company Manual.

Everest Consolidator Acquisition Corporation Receives NYSE Notice Regarding Delayed Form 10-Q Filing

Retrieved on:

Tuesday, November 28, 2023

Finance, Business, Banking, Professional Services, Other Professional Services, NYSE, Listing Rules, Security (finance), Form 10-Q, Notice, Form, Trust, NYSE Listed Company Manual

The Notice has no immediate effect on the listing of the Company’s securities on the NYSE.

Key Points:

The Notice has no immediate effect on the listing of the Company’s securities on the NYSE.
The NYSE informed the Company that, under the NYSE's rules, the Company has six months from the original due date of the Form 10-Q, or until May 20, 2024, to file the Form 10-Q and regain compliance with the Listing Rule.
The NYSE Notice also noted that the NYSE may nevertheless commence delisting proceedings at any time if it deems that the circumstances warrant.
The Company intends to file the Form 10-Q as soon as practicable to regain compliance with the Listing Rule.

Learn CW Investment Corporation Receives Noncompliance Notification from the New York Stock Exchange Due to Delayed Form 10-Q Filing

Retrieved on:

Monday, November 27, 2023

Fintech, Professional Services, Business, Finance, NYSE, Listing Rules, Security (finance), Form 10-Q, Notice, Bank statement, Form, NYSE Listed Company Manual

The Listing Rule requires timely filing of all required periodic financial reports with the SEC.

Key Points:

The Listing Rule requires timely filing of all required periodic financial reports with the SEC.
The Notice specifies that the Company can regain compliance with the Listing Rule by filing the Form 10-Q within six months from the Form 10-Q’s filing due date.
If the Company fails to file the Form 10-Q by such date, the Company may submit a request for the NYSE’s consideration to allow the Company’s securities to trade for an additional six-month trading period.
While the Company can provide no assurances as to timing, the Company plans to file the Form 10-Q as soon as practicably possible to regain compliance with the Listing Rule.

Arcus Biosciences Announces New Employment Inducement Grants

Retrieved on:

Monday, November 27, 2023

Oncology, Health, Other Science, Clinical Trials, Science, Pharmaceutical, Biotechnology, NYSE, NYSE Listed Company Manual, Compensated emancipation, Cancer, Pharmaceutical industry

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 12,600 shares of the Company’s common stock at an exercise price per share of $14.06, which was the closing price on November 24, 2023, and restricted stock units to acquire a total of 6,300 shares of the Company’s common stock.

Key Points:

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted four new employees options to purchase a total of 12,600 shares of the Company’s common stock at an exercise price per share of $14.06, which was the closing price on November 24, 2023, and restricted stock units to acquire a total of 6,300 shares of the Company’s common stock.
The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.

Fisker Files 10-Q on Nov. 22

Retrieved on:

Wednesday, November 22, 2023

There was a series of events that led to us filing late,” Chairman and CEO Henrik Fisker said.

Key Points:

There was a series of events that led to us filing late,” Chairman and CEO Henrik Fisker said.
Our team is working day and night to deliver and sell even more vehicles,” continued Fisker.
Last week, Fisker reported a new daily delivery record of 107 vehicles, up more than 120% from a month earlier.
Overall, Fisker can now see that its delivery strategy is working and the company is ready to scale.

Yelp Announces New Employee Inducement Grants Under NYSE Rule 303A.08

Retrieved on:

Monday, November 20, 2023

Apps, Applications, Technology, Marketing, Communications, Internet, Digital Marketing, Social Media, Retail, Online Retail, Yelp, NYSE, Employment, Inc., Compensated emancipation, NYSE Listed Company Manual, Professional Football Compensation Committee, Pharmaceutical industry

Yelp Inc. (NYSE: YELP), the company that connects people with great local businesses, announced that on November 14, 2023, the Compensation Committee of Yelp’s Board of Directors granted inducement restricted stock unit awards covering 36,354 shares of Yelp’s common stock to eight new non-executive employees to induce them to accept employment with Yelp.

Key Points:

Yelp Inc. (NYSE: YELP), the company that connects people with great local businesses, announced that on November 14, 2023, the Compensation Committee of Yelp’s Board of Directors granted inducement restricted stock unit awards covering 36,354 shares of Yelp’s common stock to eight new non-executive employees to induce them to accept employment with Yelp.
Each award was granted under the Yelp Inc. 2023 Inducement Award Plan and vests over a four-year period, subject to continued employment with Yelp through each vesting date.
Each award was granted as a material inducement to employment in accordance with the NYSE Listed Company Manual Rule 303A.08.

Fisker Announces Receipt of Notice of Late Filing from NYSE

Retrieved on:

Monday, November 20, 2023

The NYSE informed the Company that, under NYSE rules, the Company will have six months from November 14, 2023 to file the Form 10-Q with the SEC.

Key Points:

The NYSE informed the Company that, under NYSE rules, the Company will have six months from November 14, 2023 to file the Form 10-Q with the SEC.
The Company can regain compliance with the NYSE listing standards at any time prior to that date by filing its Form 10-Q.
The notice from the NYSE also notes that the NYSE may nevertheless commence delisting proceedings at any time if it deems that the circumstances warrant.
On November 13, 2023, the Company filed a Notification of Late Filing on Form 12b-25 (the “Form 12b-25”), indicating that the filing of its Form 10-Q would be delayed.

NYSE to Commence Delisting Proceedings with Respect to the Warrants of Offerpad Solutions Inc. (OPAD WS)

Retrieved on:

Thursday, November 16, 2023

Other Professional Services, Professional Services, Finance, NYSE Listed Company Manual, New York Stock Exchange, NYSE, Security (finance), Warrant, Exchange, Committee

The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants of Offerpad Solutions Inc. (the “Company”), every 15 warrants are exercisable for one share of Class A common stock at an exercise price of $172.50 per share (the “Warrants”) — ticker symbol OPAD WS — from the NYSE.

Key Points:

The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants of Offerpad Solutions Inc. (the “Company”), every 15 warrants are exercisable for one share of Class A common stock at an exercise price of $172.50 per share (the “Warrants”) — ticker symbol OPAD WS — from the NYSE.
Trading in the Company’s Warrants will be suspended immediately.
Trading in the Company’s Class A common stock — ticker symbol OPAD — will continue on the NYSE.
NYSE Regulation has determined that the Company’s Warrants are no longer suitable for listing based on “abnormally low” price levels, pursuant to Section 802.01D of the Listed Company Manual.

NYSE to Commence Delisting Proceedings with Respect to the Warrants of Cano Health, Inc. (CANO/WS)

Retrieved on:

Monday, November 13, 2023

Professional Services, Finance, NYSE Listed Company Manual, New York Stock Exchange, NYSE, Security (finance), Warrant, Exchange, Committee

Trading in the Company’s Warrants will be suspended immediately.

Key Points:

Trading in the Company’s Warrants will be suspended immediately.
Trading in the Company’s Class A common stock — ticker symbol CANO —will continue on the NYSE.
NYSE Regulation has determined that the Company’s Warrants are no longer suitable for listing based on “abnormally low” price levels, pursuant to Section 802.01D of the Listed Company Manual.
The NYSE will apply to the Securities and Exchange Commission to delist the Warrants upon completion of all applicable procedures, including any appeal by the Company of the NYSE Regulation staff’s decision.

Arcus Biosciences Announces New Employment Inducement Grants

Retrieved on:

Monday, November 13, 2023

Biotechnology, Other Professional Services, Health, Business, Other Health, Pharmaceutical, Professional Services, Oncology, Other Science, Research, General Health, Genetics, Science, Clinical Trials, NYSE, NYSE Listed Company Manual, Compensated emancipation, Cancer, Pharmaceutical industry

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted 12 new employees options to purchase a total of 31,200 shares of the Company’s common stock at an exercise price per share of $16.01, which was the closing price on November 8, 2023, and restricted stock units to acquire a total of 15,600 shares of the Company’s common stock.

Key Points:

Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that the Compensation Committee of the Company’s Board of Directors granted 12 new employees options to purchase a total of 31,200 shares of the Company’s common stock at an exercise price per share of $16.01, which was the closing price on November 8, 2023, and restricted stock units to acquire a total of 15,600 shares of the Company’s common stock.
The equity awards were granted pursuant to the Company’s 2020 Inducement Plan, which was approved by the Company’s Board of Directors in January 2020 pursuant to the “inducement exception” under NYSE Listed Company Manual Rule 303A.08.